Dr. Gerald Chodak has raised an interesting reason why physicians may want to think hard about the U.S. Preventive Services Task Force’s recommendation on the value of PSA testing for risk of prostate cancer. In one of his regular commentaries on the Medscape web site last Friday (under the heading “PSA screening: are we ‘falling […]![]()
